Related Experiment Video
Updated: Feb 24, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice
Kerstin Brinkmann1,2, Stephanie Grabow1,2, Craig D Hyland1
1Cancer and Haematology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Abstract:
A common therapeutic strategy to combat human cancer is the use of combinations of drugs, each targeting different cellular processes or vulnerabilities. Recent studies suggest that addition of an MCL-1 inhibitor to such anticancer drug treatments could be an attractive therapeutic strategy. Thus, it is of great interest to understand whether combinations of conventional anticancer drugs with an MCL-1 inhibitor will be tolerable and efficacious. In order to mimic the combination of MCL-1 inhibition with other cancer therapeutics, we treated Mcl-1+/- heterozygous mice, which have a ~50% reduction in MCL-1 protein in their cells, with a broad range of chemotherapeutic drugs. Careful monitoring of treated mice revealed that a wide range of chemotherapeutic drugs had no significant effect on the general well-being of Mcl-1+/- mice with no overt damage to a broad range of tissues, including the haematopoietic compartment, heart, liver and kidney. These results indicate that MCL-1 inhibition may represent a tolerable strategy in cancer therapy, even when combined with select cytotoxic drugs.
Insights
Combining MCL-1 inhibitors with chemotherapy shows promise for cancer treatment. Studies in mice indicate this combination is tolerable and may be an effective cancer therapy strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer therapy often involves drug combinations targeting various cellular pathways.
- MCL-1 inhibitors are being explored as potential additions to existing anticancer treatments.
- Understanding the tolerability and efficacy of combined MCL-1 inhibition and conventional drugs is crucial.
Purpose of the Study:
- To investigate the tolerability and potential efficacy of combining MCL-1 inhibition with conventional anticancer drugs.
- To assess the safety of co-administering chemotherapeutic agents with reduced MCL-1 protein levels.
Main Methods:
- Utilized Mcl-1+/- heterozygous mice, exhibiting approximately 50% reduced MCL-1 protein.
- Administered a wide range of chemotherapeutic drugs to these mice.
- Monitored general well-being and examined major tissues for damage.
Main Results:
- Chemotherapeutic drugs showed no significant adverse effects on the general health of Mcl-1+/- mice.
- No overt tissue damage was observed in key organs, including the hematopoietic system, heart, liver, and kidney.
- MCL-1 inhibition in combination with select cytotoxic drugs appears to be well-tolerated.
Conclusions:
- MCL-1 inhibition is a potentially tolerable strategy in cancer therapy.
- This approach may be safely combined with certain cytotoxic anticancer drugs.
- Further research into MCL-1 inhibitor combinations could lead to improved cancer treatment regimens.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...